Opko Health
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
14% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 29
2.26% more ownership
Funds ownership: 26.6% [Q3] → 28.86% (+2.26%) [Q4]
8% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 60
4% more capital invested
Capital invested by funds: $278M [Q3] → $289M (+$11.7M) [Q4]
1% less funds holding
Funds holding: 232 [Q3] → 229 (-3) [Q4]
45% less call options, than puts
Call options by funds: $9.74M | Put options by funds: $17.7M
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2.25
58%
upside
Avg. target
$2.63
85%
upside
High target
$3
111%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 27% 1-year accuracy 46 / 173 met price target | 111%upside $3 | Buy Reiterated | 7 Apr 2025 |
Barrington Research Michael Petusky 19% 1-year accuracy 13 / 69 met price target | 58%upside $2.25 | Outperform Maintained | 12 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO's common stock has been repurchased under the existing program since its authorization in July 2024.

Positive
Zacks Investment Research
3 weeks ago
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.

Positive
Reuters
1 month ago
OPKO and Entera partner to develop obesity pill
OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.

Neutral
PRNewsWire
1 month ago
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.

Positive
Zacks Investment Research
1 month ago
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.

Neutral
Zacks Investment Research
1 month ago
OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Positive
Zacks Investment Research
1 month ago
OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates
OPKO Health (OPK) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.09 per share a year ago.

Neutral
Seeking Alpha
1 month ago
OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Zerhouni - Vice Chairman and President Adam Logal - Chief Financial Officer Gary Nabel - Chief Innovation Officer Conference Call Participants Maury Raycroft - Jefferies Jeffrey Cohen - Ladenburg Thalmann Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw and Company Eduardo Martinez-Montes - H.C. Wainwright Operator Good day.

Neutral
GlobeNewsWire
1 month ago
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial.

Neutral
Zacks Investment Research
1 month ago
Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of OPKO Health (OPK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Charts implemented using Lightweight Charts™